Uncategorized

Avalyn’s upsized IPO; Alector ends another study in GSK partnership

Avalyn’s upsized IPO; Alector ends another study in GSK partnership

Published

5 hours ago

on

🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is selling over 16.5 million shares at $18 apiece. The company is set to start trading as {$AVLN} on the Nasdaq Thursday …​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version